Results 31 to 40 of about 351,954 (346)

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma [PDF]

open access: yes, 2016
Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored.
Fillerová, Regina   +9 more
core   +1 more source

Direct-to-patient research: Opportunity brings challenges

open access: yesCancer Treatment and Research Communications
Direct-to-patient (DTP) research offers promising alternatives to traditional models, potentially improving population-level data collection to understand disease initiation, progression, and response to treatment.
Anne Quinn-Young   +8 more
doaj   +1 more source

Widespread intronic polyadenylation diversifies immune cell transcriptomes

open access: yesNature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh   +8 more
doaj   +1 more source

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry [PDF]

open access: yes, 2016
Spanish Myeloma Group (GEM) and Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups: et al.Multiple myeloma remains largely incurable.
Blanco, Juan F.   +15 more
core   +1 more source

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

open access: yesBlood Advances
: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim   +9 more
doaj   +1 more source

Talquetamab in multiple myeloma

open access: yesHaematologica, 2023
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

open access: yes, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B   +6 more
core   +1 more source

Multiple Myeloma [PDF]

open access: yesClinical Journal of the American Society of Nephrology, 2006
Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotein production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral- and cell-mediated immunity, elevation of IL-6, abnormalities of the bone ...
Seema, Singhal, Jayesh, Mehta
openaire   +5 more sources

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

open access: yes, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana   +5 more
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy